Vaccine Safety Registry
Shingles Vaccine Safety
Institutional safety information on Shingrix and Zoster vaccines. Clinical data, reactogenicity profiles, and long-term surveillance metadata for adults 50+.
Medically reviewed by
Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Shingles (Herpes Zoster) presents as a localized, painful dermatomal rash resulting from the reactivation of the latent Varicella-Zoster Virus (VZV). Post-recovery from chickenpox, VZV remains dormant in neural ganglia, with reactivation probability increasing alongside immunosenescence.
Complications include postherpetic neuralgia (PHN), characterized by chronic, debilitating nerve pain. High-authority recombinant immunization protocols effectively suppress viral reactivation and mitigate long-term neuropathic sequelae.
Vaccine Formulations
Module specifics & formulations
Formulation Node
Shingrix
Preferred Institutional Standard
- Formulation: Recombinant adjuvanted zoster vaccine.
- Target: Approved for adults 50+ and immunocompromised 19+.
- Efficacy: >90% prevention rate against reactivation.
- Series: 2-dose protocol (2-6 month interval).
- Live zoster vaccine protocol terminated in 2020. Shingrix synchronization is recommended for previous recipients.
Clinical Triage
Eligibility & contraindications
Routine Protocol
- All adults 50 years and older
- Immunocompromised adults (19+)
- Individuals with prior zoster events
Special Triage
- Prior recipients of Zostavax protocol
- Chronic clinical condition profiles
- Patients on immunosuppressive maintenance
Absolute & Relative Contraindications
- Anaphylaxis to previous Shingrix dose
- Acute zoster event in progress
- Gestational or lactation status
Adverse Events
Reported reactions & surveillance
Local Reactions
- Localized pain
- Erythema
- Localized induration
Systemic Profile
- Generalized myalgia
- Lethargy/fatigue
- Cephalalgia (Headache)
- Pyrexia / shivering
Surveillance Analytics
Post-market surveillance metrics
2017
Registry Entry
200M+
Doses Synchronized
30,000
Trial Participants
Institutional Surveillance
Continuous monitoring through VAERS and global surveillance networks confirms the outstanding safety profile of Shingrix across all geriatric and high-risk cohorts.
Editorial Governance
Clinical Reviewers & Authors
Dr. Simran Kohli
MBBS, MD (General Medicine), DM (Infectious Diseases)
Infectious Diseases
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Use of Recombinant Zoster Vaccine in Immunocompromised Adults: Recommendations of the ACIP
MMWR Morbidity and Mortality Weekly Report, 71(3):80-84
- 2WHO2024Varicella and herpes zoster vaccines: WHO position paper
Weekly Epidemiological Record, 89(25):265-288
- 3FDA2024SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) Prescribing Information
U.S. Food and Drug Administration CBER, GlaxoSmithKline
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Rohan Gupta and clinically reviewed by Dr. Simran Kohli, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.